Theriva Biologics (TOVX) Liabilities and Shareholders Equity (2010 - 2026)

Theriva Biologics (TOVX) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $38.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 18.93% year-over-year to $38.2 million; the TTM figure through Mar 2026 stood at $143.2 million (down 4.57% YoY), while the FY2025 annual figure was $38.2 million, up 8.17% from the prior year.
• Liabilities and Shareholders Equity steadied at $38.2 million in Q1 2026 per TOVX's latest filing, from $38.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $89.0 million in Q1 2022 and bottomed at $30.8 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $53.6 million across 5 years, with a median of $48.7 million in 2024.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity slumped 35.98% — and 2026, when it climbed 18.93%.
• Theriva Biologics' Liabilities and Shareholders Equity stood at $71.9 million in 2022, then fell by 23.16% to $55.2 million in 2023, then plunged by 35.98% to $35.4 million in 2024, then grew by 8.17% to $38.2 million in 2025, then climbed by 0.02% to $38.2 million in 2026.
• Business Quant data shows TOVX's Liabilities and Shareholders Equity at $38.2 million in Q1 2026, $38.2 million in Q4 2025, and $30.8 million in Q3 2025.